Raloxifene similarly affects the skeletal system of male and ovariectomized female rats

Pharmacological Reports

Volumn 59, Issue 3, 2007, Pages 349-358

  Folwarczna, Joanna ^a   Śliwiński, Leszek ^a   Cegieła, Urszula ^a   Pytlik, Maria ^a   Kaczmarczyk Sedlak, Ilona ^a   Nowińska, Barbara ^a   Janiec, Waldemar ^a   Trzeciak, Henryk I ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bone; Male rats; Ovariectomized rats; Raloxifene

Indexed keywords

RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE MASS; BONE MINERAL; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; MALE; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; RAT; SKELETON; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34548139325     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med, 2006, 355, 125-137.
2. Broulik PD: Tamoxifen prevents bone loss in castrated male mice. Horm Metab Res, 2000, 32, 181-184.
3. 2+ influx. J Pharmacol Exp Ther, 2005, 312, 1266-1271.
4. Doran PM, Riggs BL, Atkinson EJ, Khosla S: Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res, 2001, 16, 2118-2125.
5. Duschek EJ, Gooren LJ, Netelenbos C: Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol, 2004, 150, 539-546.
6. Esposito E, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, Meli R: Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology, 2005, 146, 3301-3308.
7. Evans GL, Bryant HU, Magee DE, Turner RT: Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology, 1996, 137, 4139-4144.
8. Figtree GA, Lu Y, Webb CM, Collins P: Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation, 1999, 100, 1095-1101.
9. Fitts JM, Klein RM, Powers CA: Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J Androl, 2004, 25, 523-534.
10. Folwarczna J, Janiec W, Barej M, Cegiela U, Pytlik M, Kaczmarczyk-Sedlak I: Effects of nadroparin on bone histomorphometric parameters in rats. Pol J Pharmacol, 2004, 56, 337-343.
11. Folwarczna J, Janiec W, Śliwiński L: Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost, 2004, 92, 940-946.
12. Folwarczna J, Pytlik M, Janiec W: Effects of doxycycline on development of changes in histomorphometric parameters of bones induced by bilateral ovariectomy in rats. Pol J Pharmacol, 2003, 55, 433-441.
13. Fontana A, Delmas PD: Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am 2003, 32, 219-232.
14. Hoyt JA, Fisher LF, Swisher DK, Byrd RA, Francis PC. The selective estrogen receptor modulator, raloxifene. reproductive assessments in adult male rats. Reprod Toxicol, 1998, 12, 223-232.
15. 3 increases responsiveness to 17β-estradiol, dibydrotestosterone or raloxifene in primary human osteoblasts. J Steroid Biochem Mol Biol, 2004, 88, 213-219.
16. Kauffman RF, Bean JS, Fahey KJ, Cullinan GJ, Cox DA, Bensch WR: Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. J Cardiovasc Pharmacol, 2000, 36, 459-465.
17. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res, 2001, 16, 765-773.
18. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology; 2000, 141, 1338-1344.
19. Krassas GE, Papadopoulou P: Oestrogen action on bone cells. J Musculoskelet Neuronal Interact, 2001, 2, 143-151.
20. Leitzbach D, Weekler N, Madajka M, Malinski T, Wiemer G, Linz W: Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats. Arzneimittelforschung, 2005, 55, 86-92.
21. Pytlik M, Folwarczna J, Janiec W. Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int, 2004, 75, 225-230.
22. Smith CL, O'Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev, 2004, 25, 45-71.
23. Smith MR, Fallon MA, Lee H, Finkelstein JS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab, 2004, 89, 3841-384.
24. Smith MR: Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol, 2005, 2, 608-615.
25. 3: JK 1624F(2)-2 (JKF). J Steroid Biochem Mol Biol, 2006, 99, 139-146.
26. Stürmer EK, Seidlová-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM: Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res, 2006, 21, 89-96.
27. Tripp EJ, MacKay EH: Silver staining of bone prior to decalcification for quantitative determination of osteoid in sections. Stain Technol, 1972, 47, 129-136.
28. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R: Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res, 2004, 19, 1518-1524.
29. Vanderschueren D, Boonen S, Ederveen AG, de Coster R, Van Herck E, Moermans K, Vandenput L et al.: Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone, 2000, 27, 611-617.
30. Vanderschueren D, Van Herck E, Nijs J, Ederveen AG, de Coster R, Bouillon R: Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology, 1997, 138, 2301-2307.
31. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rösen R et al.: Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation, 2002, 105, 2083-2091.
32. Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A et al.: Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol, 2002, 90, 1204-1210.